Prognostic effect of hormone receptor status in early HER2 positive breast cancer patients

Hematology/ Oncology and Stem Cell Therapy

Volumn 3, Issue 3, 2010, Pages 109-115

  Gómez, Henry L ^a   Castañeda, Carlos A ^a   Vigil, Carlos E ^a   Vidaurre, Tatiana ^a   Velarde, Raúl G ^a   Cruz, Wilder R ^a   Pinto, Joseph A ^a   Suazo, Juan F ^a   Garcés, Milko R ^a   Neciosup, Silvia P ^a   Vallejos, Carlos S ^a  

^a INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR; TAMOXIFEN; TAXANE DERIVATIVE;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; OVERALL SURVIVAL; PROGNOSIS;

EID: 79551648526     PISSN: 16583876     EISSN: None     Source Type: Journal    
DOI: 10.5144/1658-3876.2010.109     Document Type: Article

References (24)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2): 74-108.
2. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124(7): 966-78.
3. Sjogren, S, Inganäs M, Lindgren A, Holmberg L, Bergh J. Prognostic and predictive value of cerbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998; 16(2): 462-9.
4. Decker T, Hungermann D, Bocker W. [Prognostic and predictive factors of invasive breast cancer: update 2009] in German. Pathologe 2009; 30(1): 49-55.
5. Prat A, Baselga J. The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2. Nat Clin Pract Oncol 2008; 5(9): 531-42.
6. Russell KS, Hung MC. Transcriptional repression of the neuprotooncogene by estrogen stimulated estrogen receptor. Cancer Res 1992; 52(23): 6624-9.
7. Rasmussen MMR, Lykkesfeldt, P. Dell'Orto, B. Del Curto, K. L. Henriksen, M. G. Mastropasqua, B. Thürlimann and G. Viale, Central assessment of ER, PgR and HER2 in BIG 1-98 evaluating letrozole (L) compared to tamoxifen (T) as initial adjuvant en-docrine therapy for postmenopausal women with hormone receptor-positive breast cancer. in ASCO Annual Meeting Proceedings 2007. 2007: Journal of Clinical Oncology.
8. Dowsett M, Allred C, Knox J, Quinn E, Salter J, Wale C, Cuzick J, Houghton J, Williams N, Mallon E, Bishop H, Ellis I, Larsimont D, Sasano H, Carder P, Cussac AL, Knox F, Speirs V, Forbes J, Buzdar A. Relationship Between Quantitative Estrogen and Progesterone Receptor Expression and Human Epidermal Growth Factor Receptor 2 (HER-2) Status With Recurrence in the Arimidex, Tamoxifen, Alone or in Combination Trial. J Clinical Oncol. 2008; 26: 1059-1065
9. Kurokawa H, Arteaga CL. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer. Clin Cancer Res 2001; 7(12 Suppl): 4436s-4442s; discussion 4411s-4412s.
10. Carlson RW. NCCN Practice Guidelines in Oncology. Breast cancer. 2008; http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf].
11. Buzdar AU. Role of biologic therapy and chemotherapy in hormone receptor- and HER2-posi-tive breast cancer. Ann Oncol 2009; 20(6): 993-9.
12. Kaplan EL. Nonparametric estimation from in-complete observations. J Am Stat Assoc. 1958;53: 457-481.
13. Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, Bellon JR, Wong JS, Smith BL, Harris JR. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol 2008; 26(14): 2373-8.
14. Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005; 23(29): 7350-60.
15. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295(21): 2492-502.
16. Untch M, Gelber RD, Jackisch C, Procter M, Baselga J, Bell R, Cameron D, Bari M, Smith I, Leyland-Jones B, de Azambuja E, Wermuth P, Khasanov R, Feng-Yi F, Constantin C, Mayordomo JI, Su CH, Yu SY, Lluch A, Senkus-Konefka E, Price C, Haslbauer F, Suarez Sahui T, Srimuninnimit V, Colleoni M, Coates AS, Piccart-Gebhart MJ, Goldhirsch A; HERA Study Team. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008; 19(6): 1090-6.
17. Park YH, Lee S, Cho EY, Choi YL, Lee JE, Nam SJ, Yang JH, Ahn JS, Im YH. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status. Cancer Chemother Pharmacol, 2009 Dec 3. [Epub ahead of print].
18. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer E P. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006; 295(14): 1658-67.
19. Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Win-er EP, Hudis CA, Ellis MJ, Berry DA; Cancer and Leukemia Group B (CALGB) Investigators. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007; 357(15): 1496-506.
20. Johnston SR. Enhancing the efficacy of hormonal agents with selected targeted agents. Clin Breast Cancer 2009; 9 Suppl 1: S28-36.
21. Johnston S, Pegram M, Press M. Lapatinib combined with letrozole vs letrozole alone for front-line postmenopausal hormone receptor positive (HR+) metastatic breast cancer (MBC): first results from the EGF30008 Trial (abstract 46). The 31st Annual CTRC-AACR San Antonio Breast Cancer Symposium. 2008.
22. Mackey, JR, Kaufman, B, Clemens, M. Trastu-zumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer (abstract). The San Antonio Breast Cancer Symposium. 2006.
23. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas E P, Lingle WL, Klein PM, Ingle JN, Wol-mark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-84.
24. Vallejos CS, Gómez HL, Cruz WR, Pinto JA, Dyer RR, Velarde R, Suazo JF, Neciosup S P, León M, de la Cruz MA, Vigil CE. Breast cancer classifi-cation according to immunohistochemistry markers: subtypes and association with clinicopathologic variables in a peruvian hospital database. Clin Breast Cancer. 2010;10:294-300.